COMMUNIQUÉS West-GlobeNewswire

Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

12/09/2018 - 13:00

FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions [...]

Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®

12/09/2018 - 13:00

MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a specialty pharmaceutical [...]

Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth

12/09/2018 - 13:00

Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth Research Triangle Park, NC and Cambridge, UK, September 12, 2018 -- Inivata , a leader in liquid biopsy, today announces the strengthening of [...]

Aleafia Completes Second Harvest with Sale to Licensed Producer Imminent

12/09/2018 - 13:00

Clinic Operations and Cannabis Sales Providing Immediate Multiple Income Streams TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one [...]

Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

12/09/2018 - 13:00

- Former CMO of Schering-Plough Joins Cyclacel Board - BERKELEY HEIGHTS, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a [...]

EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

12/09/2018 - 12:00

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of [...]

Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).

12/09/2018 - 11:01

Press release Malmö, September 12, 2018 Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD). Acarix AB (publ) ("Acarix") reports first sales in [...]

Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival

12/09/2018 - 11:00

SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]

Solon Eiendom ASA – Primary insider notification

12/09/2018 - 08:30

(Oslo, Norway, September 11, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 30.000 shares in Solon Eiendom ASA at a price of NOK 29. Following this [...]

Shire plc : Rule 2.9 Announcement

12/09/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 September 2018 [...]

Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress

12/09/2018 - 08:00

Late breaking oral presentation will provide additional detail around previously reported top-line results LONDON, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a [...]

Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease

12/09/2018 - 08:00

SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI ® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE Marketing Authorization will enable patient access to VEYVONDI ® [...]

Notice of Changes in the Supervisory Council of JSC Olainfarm

12/09/2018 - 07:56

The Joint Stock Company Olainfarm hereby informs about the receipt of the notice from the member of the Council of the Joint Stock Company "Olainfarm" Signe Baldere-Sildedze on leaving the Supervisory Council as of [...]

DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers

12/09/2018 - 07:31

Montrouge, France, September 12, 2018 DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers No safety concerns identified by independent DSMB Part B expected to [...]

DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide

12/09/2018 - 07:31

Montrouge, France, le 12 septembre (07h30 CEST), 2018 DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide Le DSMB [...]

Novartis survey shows psoriasis patients want treatment effect beyond clear skin

12/09/2018 - 07:16

New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions[1] A [...]

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

12/09/2018 - 07:01

FDA to review supplemental Biologics License Application for Praluent ® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events FDA also recently approved Praluent label update for [...]

La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardi...

12/09/2018 - 07:01

La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent ® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardiovasculaires majeurs [...]

INNATE PHARMA : first patient in the Phase I study of IPH5401 in combination with durvalumab

12/09/2018 - 07:01

Innate PHARMA announces enrollment of first patient in the phase i study of IPH5401 in combination with durvalumab (IMFINZI ® ) in solid tumors IPH5401 is a first-in-class antibody targeting the C5a receptor expressed [...]